Chengdu Great Southwest Pharmaceutical

Chengdu Kanghong Pharmaceutical Group is a leading Chinese pharmaceutical company focused on the research, development, and commercialization of innovative drugs in the fields of ophthalmology, central nervous system (CNS), and digestive diseases. Founded in 1996 and headquartered in Chengdu, the company is best known for its flagship biologic product, Conbercept (Lumitin), a multi-target VEGF inhibitor used to treat various retinal diseases. Kanghong operates a diverse portfolio that includes chemical drugs, biologics, and modern Traditional Chinese Medicine (TCM). The company is actively expanding its pipeline into advanced modalities such as AAV-based gene therapies, synthetic biology-derived natural products, and antibody-drug conjugates. Publicly traded on the Shenzhen Stock Exchange, Kanghong maintains a strong commitment to innovation through its national-level enterprise technology centers and international R&D collaborations.